IGF1 and autism: We are at present using these methods to track longitudinal changes in spontaneous behavior before, during and after treatment of an FDA-approved clinical trial drug using insulin-like growth factor 1 in children with a diagnosis of autism of known etiology [specifically, in children with Phellan-McDermid syndrome (Phelan and Rogers, 1993)].